Iqvia Holdings Inc (NYSE:IQV) Director John Connaughton sold 1,163,191 shares of the business’s stock in a transaction dated Thursday, November 30th. The stock was sold at an average price of $102.00, for a total transaction of $118,645,482.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

John Connaughton also recently made the following trade(s):

  • On Tuesday, September 19th, John Connaughton sold 1,030,429 shares of Iqvia stock. The stock was sold at an average price of $94.87, for a total transaction of $97,756,799.23.

Iqvia Holdings Inc (IQV) opened at $101.00 on Wednesday. Iqvia Holdings Inc has a fifty-two week low of $74.73 and a fifty-two week high of $110.67. The company has a debt-to-equity ratio of 1.29, a current ratio of 1.22 and a quick ratio of 1.22. The firm has a market cap of $21,526.60, a P/E ratio of 23.35, a P/E/G ratio of 1.68 and a beta of 0.61.

Iqvia (NYSE:IQV) last issued its quarterly earnings results on Thursday, October 26th. The medical research company reported $1.19 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.14 by $0.05. Iqvia had a net margin of 0.58% and a return on equity of 12.60%. The company had revenue of $2.02 billion for the quarter, compared to the consensus estimate of $2.01 billion. During the same quarter in the prior year, the company earned $1.00 EPS. Iqvia’s quarterly revenue was up 77.6% on a year-over-year basis. analysts expect that Iqvia Holdings Inc will post 4.62 earnings per share for the current year.

A number of equities analysts have commented on IQV shares. Barclays boosted their target price on shares of Iqvia from $100.00 to $120.00 and gave the stock an “overweight” rating in a report on Friday, October 27th. Morgan Stanley boosted their target price on shares of Iqvia from $96.00 to $121.00 and gave the stock an “overweight” rating in a report on Thursday, November 9th. KeyCorp reiterated a “sector weight” rating and issued a $100.00 target price on shares of Iqvia in a report on Friday, November 10th. Zacks Investment Research upgraded shares of Iqvia from a “hold” rating to a “buy” rating and set a $121.00 price objective on the stock in a report on Tuesday, October 31st. Finally, SunTrust Banks restated a “hold” rating and set a $114.00 price objective on shares of Iqvia in a report on Friday, November 3rd. Nine equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $105.23.

WARNING: “John Connaughton Sells 1,163,191 Shares of Iqvia Holdings Inc (IQV) Stock” was first reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this article on another website, it was copied illegally and reposted in violation of international copyright legislation. The original version of this article can be read at https://theolympiareport.com/2017/12/06/john-connaughton-sells-1163191-shares-of-iqvia-holdings-inc-iqv-stock.html.

Iqvia Company Profile

IQVIA Holdings Inc, formerly Quintiles IMS Holdings, Inc, provides integrated information and technology-enabled healthcare services. The Company operates through segments, including Commercial Solutions; Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offerings include national information offerings, sub-national information offerings, technology solutions, and workflow analytics and consulting services.

Insider Buying and Selling by Quarter for Iqvia (NYSE:IQV)

Receive News & Ratings for Iqvia Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia Holdings Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.